English |
Français
Maître de Conférences
Faculté des Sciences et Technologies - Nancy
Université de Lorraine
+ 33 03 72 74 57 00 | samina.akbar@univ-lorraine.fr
Foods, 14 (13), pp. 2235-2235.
Hafeez, Z., Beaubier, S., Aymes, A., Christophe, S., Akbar, S., Kapel, R., Miclo, L.
Lactic acid bacteria are well known for hydrolyzing milk proteins, but their application to
plant proteins remains limited. This study evaluated the ability of the cell-wall-anchored
PrtS protease from two Streptococcus thermophilus strains to hydrolyze rapeseed albumins
(RAs), aiming to generate bioactive peptides with potential food functionality. The specific
activity of PrtS was first determined using a chromogenic substrate. RAs were then
hydrolyzed using 10X- and 100X-concentrated cell pellets of each strain to assess the hydrolysis
kinetics and the enzymatic mechanism. The results showed concentration-dependent
hydrolysis, with protein conversion and the degree of hydrolysis increasing threefold at
100X for both strains. Despite the increased hydrolysis, the peptides produced had similar
average sizes, averaging at five amino acids, indicating a consistent “one-by-one” cleavage
mechanism. The in vitro testing of the RA hydrolysates produced with 100X PrtS from
S. thermophilus LMD-9 revealed dose-dependent antioxidant activity comparable to native
RAs. Importantly, unlike native RAs, these hydrolysates did not induce increased secretion
of the pro-inflammatory mediator IL-8 in inflamed HT-29 cells, suggesting a reduced proinflammatory
potential. These findings demonstrate that PrtS protease from S. thermophilus
can effectively hydrolyze rapeseed proteins to produce functional hydrolysates with improved
bioactivity profiles. Such hydrolysates have promising applications as functional
ingredients in plant-based food products, contributing both to health benefits and potential
food preservation through antioxidant activity.
Microbial Pathogenesis, 207 (6), pp. 107859-107859.
Siddique, A., Ali, R., Andleeb, S., Akbar, S., Hafeez, Z., Imran, M., Syoc, E.V., Yue, M., Ganda, E., Rahman, A.
Probiotics can provide an eco-friendly alternative solution to improve poultry production and disease resistance. Considering safer and more effective probiotic strains from cultured species, this study included three host-associated probiotics (HAPs): Limosilactobacillus reuteri PFS4, Enterococcus faecium PFS13, and PFS14, previously isolated from poultry gut. This study evaluated the effects of three HAPs blend and a commercial probiotic blend (ProtexinR) on broiler growth, intestinal morphology, serum immunoglobulins, and cecal microflora challenged with two fluoroquinolone-resistant Salmonella Typhimurium (ST) and Salmonella Enteritidis (SE). A total of 240-day-old broiler chicks were randomly assigned to six treatment groups (n = 40 in each group): negative control (NC), positive control (PC), HAPs control blend (IPRO-) without ST and SE challenge, HAPs blend with ST and SE challenge (IPRO+), Commercial probiotic (ProtexinR) blend with ST and SE challenge (CM+), Commercial probiotic (ProtexinR) control (CM-) blend without ST and SE challenge. Growth parameters, including body weight gain (BWG), average feed intake (AFI), and feed conversion ratio (FCR), along with microbial populations, were assessed weekly. Meanwhile, gut morphology, relative organ weight, and serum immunoglobulin levels were evaluated on days 7 and 28. The chicks infected with ST and SE were depressed, had high mortality (20 %), and reduced BWG. The growth performance parameters were significantly improved (p ≤ 0.005) in all groups administered probiotics, with the IPRO- group exhibiting the highest results. Similarly, light microscopy findings showed that all probiotic-fed groups significantly (p ≤ 0.005) improved their gut morphology compared to the positive control group. Both HAPs and commercial probiotic blend treatments increased serum IgA and IgG compared with the PC (p ≤ 0.001). IPRO+ treatment significantly (p ≤ 0.001) increased cecal populations of total Lactobacillus and total Enterococcus, while reducing cecal and liver populations of Salmonella. In conclusion, the use of HAPs showed better growth performance and enhanced MDR Salmonella control, suggesting that the poultry sector should prioritize the development and application of probiotics derived from host-specific strains rather than other sources.
Akbar, S., Rahman, A., Ahmad, N., Muhammad, I., Hafeez, Z.
Polyunsaturated fatty acids (PUFAs), notably omega-3 (n-3) and omega-6 (n-6), have received much attention owing to their multifaceted effects not only in the management of diverse pathological conditions but also in the maintenance of overall health of an individual. A disproportionately high n-6 to n-3 ratio contributes to the development of various disorders including cancer, which ranks as a leading cause of death worldwide with profound social and economic burden. Epidemiological studies and clinical trials combined with the animal and cell culture models have demonstrated the beneficial effects of n-3 PUFAs in reducing the risk of various cancer types including breast, prostate and colon cancer. The anti-cancer actions of n-3 PUFAs are mainly attributed to their role in the modulation of a wide array of cellular processes including membrane dynamics, apoptosis, inflammation, angiogenesis, oxidative stress, gene expression and signal transduction pathways. On the contrary, n-6 PUFAs have been shown to exert pro-tumor actions; however, the inconsistent findings and controversial data emphasize upon the need to further investigation. Nevertheless, one of the biggest challenges in future is to optimize the n-6 to n-3 ratio despite the genetic predisposition, age, gender and disease severity. Moreover, a better understanding of the potential risks and benefits as well as the cellular and molecular mechanisms of the basic actions of these PUFAs is required to explore their role as adjuvants in cancer therapy. All these aspects will be reviewed in this chapter.
Arteriosclerosis, Thrombosis, Vascular Biology 2012, 18-20 Avril, Chicago, Etats Unis.
Hanse, M., Stenger, C., Akbar, S., Pinçon, A., Yen, F.T.
FEBS Congress, 25-30 Juin, Turin, Italie.
Hanse, M., Stenger, C., Akbar, S., Malaplate-Armand, C., Olivier, J.-L., Oster, T., Yen, F.T.
FEBS Congress, 25-30 Juin, Turin, Italie.
Stenger, C., Hanse, M., Akbar, S., Oster, T., Yen, F.T.
